Pathogenesis of human ACP -- Transcriptomic and Genomic Analyses of Human Craniopharyngioma -- Genetically Modified Mouse Models of Adamantinomatous Craniopharyngioma -- Clinical Diagnosis of Human ACP -- Endocrine Deficits in Patients with Human Craniopharyngioma -- Obesity and metabolic disturbances in Adamantinomatous Craniopharyngioma Patients -- Radiology and Radiotherapy of Craniopharyngioma -- Surgical Treatment of Human ACP -- Intracystic Administration of Interferon-Alpha for Reduction of Cystic Tumour Burden -- Long-term Management and Clinical Trials in Adamantinomatous Craniopharyngioma.

This astute volume brings together the latest expert research on adamantinomatous craniopharyngiomas (ACPs). ACPs are histologically benign but clinically aggressive tumors exhibiting a high propensity for local invasion into the hypothalamus, optic and vascular structures. These tumors, as well as the current treatments, may result in pan-hypopituitarism, diabetes insipidus, morbid obesity followed by type II diabetes mellitus, blindness, as well as serious behavioral and psychosocial impairments. Exploring in detail advances in both the understanding of tumor biology as well as clinical advances in patient management are explored in detail, this book will also look towards potential new treatment approaches. Basic Research and Clinical Aspects of Adamantinomatous Craniopharyngioma is the first book compiling all current research on ACPs. Mouse and human studies have unequivocally demonstrated that mutations in CTNNB1 encoding -catenin underlie the etiology of the majority, if not all ACP tumors. Genetic studies in mice have shown that ACPs are tumors of the pituitary gland and not of the hypothalamus as previously thought, and are derived from Rathke’s pouch precursors. In addition, a role for tissue-specific adult pituitary stem cells has been revealed as causative of ACP. Together, these studies have provided novel insights into the molecular and cellular etiology as well as the pathogenesis of human ACP. Finally, this volume covers new treatment approaches that have been shown to be effective both in reducing ACP burden as well as reducing the morbidity associated with therapy. .